There have been numerous possible anti-Alzheimers drugs which have 
failed to live up to their original promise. This one looks more 
promising than many but is still not a certainty. Australian and and 
Swedish researchers.

        http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=43289


Cut / paste / interpret / interpolate:

Works (if it does) by combating interaction of metals and proteins 
leading to toxic a-beta oligomer formation in the brain.

About to undergo Phase IIa study - randomized, double-blind, 
placebo-controlled design, in which Alzheimer's disease patients will 
receive three (3) months of either one of three oral doses of PBT2, or 
placebo. In addition to examining safety and tolerability, the study 
will investigate the ability of PBT2 to affect multiple cerebrospinal 
fluid (CSF) and blood biomarkers of Alzheimer's disease during the 
treatment period. Outcomes will include measures of CSF a- beta and 
tau levels as well as neurocognitive and behavioral changes.

Expected / hoped for results are liable to be significant enough to be 
visible over this relatively short time scale.

________

Prana is an Australian company.
Discoverers appear to be Australian.
Trials are being carried out in Sweden.

If successful early introduction in Europe is possible due to 
legislation aimed at allowing introduction or somewhat less than 
usually scrutinised medicines for critical diseases with no known 
cures.





-- 
http://www.piclist.com PIC/SX FAQ & list archive
View/change your membership options at
http://mailman.mit.edu/mailman/listinfo/piclist